# A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

> **NCT01009086** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 615 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ustekinumab 45 mg
- **DRUG:** Ustekinumab 90 mg

## Key facts

- **NCT ID:** NCT01009086
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-10
- **Final completion:** 2013-05
- **Target enrollment:** 615 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009086, "A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01009086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*